Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly And Co

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

Benzinga

The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma

Concert Pharmaceuticals Inc (NASDAQ:CNCE) has released highly positive Phase 3 data for their alopecia areata drug CTP-543 from the THRIVE-AA1 trial. Mizuho says that the efficacy supports its view that CTP-543 potentially has best-in-class efficacy amongst the three main oral JAK inhibitors in late-stage development for alopecia areata (CTP-543, Eli Lilly And Co's (NYSE: LLY)…

Benzinga

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Eli Lilly Shares Are Rising Today

Eli Lilly And Co (NYSE: LLY) shares are trading higher by 3.58% at $296.48 after the company announced the CHMP has issued a positive opinion for OLUMIANT for the treatment of adults with severe alopecia areata.

Benzinga

Why Eli Lilly Shares Are Trading Higher Today

The FDA approved Eli Lilly And Co's (NYSE:LLY) injected drug tirzepatide, which has the brand name Mounjaro (tirzepatide), to help improve blood sugar control in adults with type 2 diabetes. The approval covers tirzepatide as an adjunct to diet and exercise. As the first and only FDA-approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1…

Benzinga

Eli Lilly, Novo Nordisk, Sanofi Accused Of Artificially Raising Insulin Prices

Arkansas has accused Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Sanofi SA (NASDAQ:SNY), and three of the largest pharmacy benefit managers (PBMs) of artificially driving up insulin prices. The complaint, filed by Arkansas Attorney General Leslie Rutledge, alleges the defendants devised a scheme in which the Big Pharmas would "artificially and willingly raise their…

Benzinga

Eli Lilly's Olumiant Becomes First FDA Approved Immunomodulatory Treatment For COVID-19

The FDA approved Eli Lilly And Co's (NYSE:LLY) Olumiant (baricitinib) for COVID-19 in hospitalized adults requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Olumiant is the first immunomodulatory treatment for COVID-19 to receive FDA approval. The FDA first issued an emergency use authorization (EUA) for Olumiant combined with remdesivir to treat…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Benzinga

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Benzinga

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

Eli Lilly And Co (NYSE: LLY)

Benzinga

Lilly Presents Updated Data On Retevmo In Advanced RET Fusion-Positive Lung Cancer

Eli Lilly And Co (NYSE:LLY) announced updated data from the Phase 1/2 LIBRETTO-001 trial of Retevmo (selpercatinib) in patients with RET fusion-positive non-small cell lung cancer (NSCLC). The updated analysis utilized a June 15, 2021, data cut-off. Among 247 patients previously treated with platinum chemotherapy, the confirmed objective response rate (ORR) was 61.1% and 84.1%…

Benzinga

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

Benzinga

Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).

Benzinga

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients

According to a British study, Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) reduced the risk of death in hospitalized COVID-19 patients by 13%. According to a Reuters report, more than 8,000 patients were administered baricitinib in addition to standard of care in the RECOVERY Trial. Results showed that 546 patients…

Benzinga

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

Benzinga

Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport

Eli Lilly And Co (NYSE: LLY)

Benzinga

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

Benzinga

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab

The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was conducted only in China and that its results did not apply to U.S. patients.

Benzinga

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Benzinga

Lilly To Inject $1B In New Manufacturing Facility In North Carolina, US

Eli Lilly And Co (NYSE: LLY)

Benzinga

Eli Lilly Plans To Invest €400M In Manufacturing Facility In Ireland: Report

Eli Lilly And Co (NYSE: LLY) plans to invest more than €400 million into a new manufacturing facility in Limerick, Ireland, according to a

Benzinga

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

Benzinga

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.